Figure S12 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

(A) Cell viability for the combination of idelalisib and the ERBB inhibitor lapatinib in parental and resistant by MTT assay (72h). Bars correspond to the mean of two independent experiments. Error bars represent standard deviation of the mean. Table contains p-values from a moderated t-test comparing each combination to idelalisib as single agent. The benefit of the combination was assessed both as synergism according to the Chou-Talalay combination index (CI, synergistic: CI<0.9, additive: CI~1, antagonistic: CI>1) (B) (2) and as potency (x-axis, synergistic: potency>0.5, additive: 01, additive: 010, additive 0>ZIP>10, antagonistic: ZIP<0) and Highest Single Agent (HSA, right; synergistic HSA>10, additive: 0>HSA>10, antagonistic HSA<0), in additional lymphoma cell lines including the DLBCL lines TMD8, and OCILY10, and the MCL models SP53 and UPN1.